Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Controlled Clinical Trial
. 2006 Aug;33(8):887-92.
doi: 10.1007/s00259-006-0077-7. Epub 2006 Apr 4.

Routine use of FDG-PET scans in melanoma patients with positive sentinel node biopsy

Janne Horn  1 , Jørgen Lock-Andersen, Helle Sjøstrand, Annika Loft
Affiliations
Controlled Clinical Trial

Routine use of FDG-PET scans in melanoma patients with positive sentinel node biopsy

Janne Horn et al. Eur J Nucl Med Mol Imaging. 2006 Aug.

Abstract

Purpose: Positron emission tomography (PET) scanning is an efficient and well-known diagnostic tool in various malignant disorders. However, the utility of PET as a clinical routine screening procedure for the detection of subclinical metastases in stage III melanoma patients has not yet been established.

Methods: Thirty-three patients with cutaneous malignant melanoma and subclinical lymph node metastases diagnosed by sentinel node biopsy (SNB) were submitted to( 18)F-fluoro-2-deoxy-D: -glucose (FDG) whole-body PET scanning within 100 days after SNB and wide local excision. Before PET scanning, patients were screened conventionally and found to be without evidence of further dissemination. Positive PET scan findings were evaluated by computed tomography scanning, magnetic resonance imaging and ultrasonography. Biopsy was performed whenever possible. The median follow-up was 15 months (range 6-39 months).

Results: Nine patients (27%) had a positive PET scan performed after SNB and WLE. On verification, four cases (12%) were found to be true positive for melanoma metastasis and were thus upgraded from stage III to stage IV. Furthermore, one patient (3%) had another primary malignancy (prostate carcinoma), and two (6%) were found to have non-malignant lesions. Two PET-positive patients (6%) refused further investigations. In one case (3%) the PET scan was false negative. Twenty-three (69%) PET scans were true negative.

Conclusion: In a number of stage III melanoma patients with positive SNB, postoperative whole-body FDG-PET scanning revealed further melanoma dissemination not found by conventional screening methods and thus identified these cases as stage IV. Relevant therapy can accordingly be instituted earlier on the basis of FDG-PET scanning.

PubMed Disclaimer

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Melanoma Res. 1996 Aug;6(4):325-9 - PubMed
    1. Clin Nucl Med. 2000 Jan;25(1):48-51 - PubMed
    1. Scand J Plast Reconstr Surg Hand Surg. 2006;40(1):24-31 - PubMed
    1. J Clin Oncol. 2001 Aug 15;19(16):3622-34 - PubMed
    1. Radiology. 2004 May;231(2):305-32 - PubMed

Publication types

MeSH terms

LinkOut - more resources